In patients with ALK-positive NSCLC, the use of LAT in extracranial oligoprogressive disease with continuation of crizotinib (N = 14/38) showed an improved PFS (17 vs 9.1 months), with local control rate of 86% 12 months after SBRT. The gene discussed is ALK; the disease is non-small cell lung carcinoma.